Fig. 1 · Structure

Documents & Downloads

Sabutoclax

Cat. No. A12823 CAS 1228108-65-3

Bcl-2 inhibitor

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.

In Stock

Publications for Sabutoclax

1 publication citing this product

  1. Christopher D. Graham, .et al. , Oncotarget, 2017, Jan 31; 8(5): 8670-8678 PMID: 28055968

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Sabutoclax (BI-97C1), tested as optically resolved compound 11, displaced BH3 peptides from Bcl-XL, Bcl-2, Mcl-1 and Bfl-1 in fluorescence-polarization assays. Reported IC50 values were 0.31, 0.32, 0.20 and 0.62 µM, respectively. These biochemical endpoints describe the tested material and assay conditions. [1]

Cellular selectivity requires separate assessment. In a later functional panel, sabutoclax showed limited direct mitochondrial activity at concentrations >1 µM, including activity in BAX/BAK-deficient mitochondria. The authors concluded that it did not meet their functional criteria for a potent direct BH3 mimetic; biochemical peptide displacement alone does not establish selective cellular action. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Mcl-1 0.20 μM
Bcl-xL 0.31 μM
Bcl-2 0.32 μM
Bfl-1 0.62 μM

Cellular Effect

Cell Line Activity Value Description Reference
NCI-H1299 EC50 3.2 μM Cytotoxicity against human H1299 cells assessed as cell viability after 72 hrs by ATP-LITE assay [PMID: 19555126]
NCI-H460 EC50 0.33 μM Cytotoxicity against human H460 cells assessed as cell viability after 72 hrs by ATP-LITE assay [PMID: 19555126]
NCI-H460 EC50 0.47 μM Cytotoxicity against human H460 cells after 3 days by ATP-LITE assay [PMID: 20443627]
PC-3 EC50 2.45 μM Cytotoxicity against human PC3 cells after 3 days by ATP-LITE assay [PMID: 20443627]

In Vitro Studies

In human T265-2c malignant peripheral nerve sheath tumor cells, sabutoclax (6 µM, 24 h) reduced CXCL12 mRNA and viable cell number relative to untreated cells. The study identifies its reagent as AdooQ A12823. These concurrent responses do not by themselves establish a direct CXCL12 target or a sabutoclax-specific PARP1 mechanism. [3]

BH3-peptide displacement from antiapoptotic Bcl-2 family proteins

Biochemical assay · Recombinant Bcl-XL, Bcl-2, Mcl-1 and Bfl-1 in fluorescence-polarization displacement assays. [1]

Compound 11 displaced BH3 peptides with submicromolar IC50 values in the reported assay panel. These are displacement endpoints, not cellular treatment concentrations or proof of selective cellular mechanism.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Bcl-XL BH3-peptide displacementIC50 0.31 ± 0.05 µM[1]
Bcl-2 BH3-peptide displacementIC50 0.32 ± 0.05 µM[1]
Mcl-1 BH3-peptide displacementIC50 0.20 ± 0.02 µM[1]
Bfl-1 BH3-peptide displacementIC50 0.62 ± 0.04 µM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Compound concentration-response series; IC50 values are assay results.
Exposure duration
Bcl-XL: 10 min preincubation, then 30 min with peptide; Bcl-2/Mcl-1: 2 min preincubation, then 10 min with peptide.
Method
Competitive fluorescence polarization in PBS; wild-type/mutant Bak peptide controls described.
Reported limits
Bfl-1-specific peptide/incubation conditions are not separately detailed in the retrieved main methods; no SI was retrieved.
Methods and source locations

Compound reported in the paper: Sabutoclax; Compound label in the paper: Compound 11 (BI-97C1)

Reported research material; no equivalence to a current Adooq lot or independent stereochemical lot verification is established.

Table 2; Figure 2A; Experimental Section: Fluorescence Polarization Assays (FPAs)

Bcl-XL BH3-peptide displacement: Competitive fluorescence polarization; mean ± SE, three independent experiments per FPA methods. — Table 2, compound 11 row; Experimental Section: Fluorescence Polarization Assays (FPAs)

Bcl-2 BH3-peptide displacement: Competitive fluorescence polarization; mean ± SE, three independent experiments per FPA methods. — Table 2, compound 11 row; Experimental Section: Fluorescence Polarization Assays (FPAs)

Mcl-1 BH3-peptide displacement: Competitive fluorescence polarization; mean ± SE, three independent experiments per FPA methods. — Table 2, compound 11 row; Experimental Section: Fluorescence Polarization Assays (FPAs)

Bfl-1 BH3-peptide displacement: Competitive fluorescence polarization; mean ± SE, three independent experiments per FPA methods. — Table 2, compound 11 row; Experimental Section: Fluorescence Polarization Assays (FPAs)

CXCL12 expression and viable cell number in T265-2c MPNST cells

Cell-based study · Human NF1-derived T265-2c malignant peripheral nerve sheath tumor cells. [3]

Sabutoclax at 6 µM for 24 h reduced CXCL12 mRNA and viable cell number relative to untreated cells. Separate single-agent comparator treatments were AT101, ABT-737, obatoclax and, for the expression assay, desferrioxamine.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CXCL12 mRNA relative to untreated T265-2c cellsqualitative reduction Reduced; p < 0.05 versus untreated (Figure 2).[3]
Viable T265-2c cell number relative to untreated cellsqualitative reduction Reduced; p < 0.01 versus untreated (Figure 4 caption).[3]

Literature-Reported Treatment Conditions

Treatment concentration
6 µM
Exposure duration
24 h
Method
qRT-PCR for CXCL12, normalized to 18S by ΔΔCT; calcein-AM viable-cell assay; treatment medium contained 2% FBS.
Co-treatment
None; comparator drugs were separate treatment groups.
Reported limits
Solvent vehicle and catalog lot/purity not specified in the read main text. Untreated rather than a separately described solvent control was used.
Methods and source locations

Compound reported in the paper: Sabutoclax; Compound label in the paper: SBX

Reported research material; no equivalence to a current Adooq lot or independent stereochemical lot verification is established.

Results s2_2; Figures 2 and 4A; Methods s4_1–s4_3, s4_5 and s4_7

CXCL12 mRNA relative to untreated T265-2c cells: qRT-PCR; mean ± SD; ANOVA followed by Dunnett’s post-hoc test. — Figure 2 (SBX 6 µM); Results s2_2; Methods s4_5 and s4_7

Viable T265-2c cell number relative to untreated cells: Calcein-AM conversion; mean ± SD; ANOVA followed by Dunnett’s post-hoc test. — Figure 4A (SBX 6 µM); Methods s4_3 and s4_7

Functional testing of mitochondrial activity and intact-cell toxicity

Cell-based study · Murine leukemia model lines dependent on human BCL-2, BCL-XL, MCL-1 or BFL-1, plus a BAX/BAK double-knockout control line. [2]

In paired concentration-response assays, sabutoclax preferentially killed MCL-1- and BFL-1-dependent intact cells, but its limited mitochondrial activity at higher concentrations was also seen in BAX/BAK-deficient cells. It did not meet this study’s functional criteria for a potent direct BH3 mimetic.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Direct mitochondrial cytochrome c release across dependency panel including BAX/BAK DKOfunctional specificity Limited mitochondrial activity at >1 µM; activity also in BAX/BAK-deficient mitochondria, per Discussion.[2]
Intact-cell killing in the antiapoptotic dependency panelmodel-dependent toxicity Preferential killing of MCL-1- and BFL-1-dependent cells; does not establish direct MCL-1 antagonism.[2]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response series; Discussion identifies mitochondrial activity at concentrations >1 µM.
Exposure duration
1 h for direct mitochondrial iBH3 assay; 24 h for intact-cell Annexin V assay.
Method
Cytochrome c loss by flow cytometry after exposure in digitonin-permeabilized cells; parallel Annexin V/Hoechst testing in intact cells.
Vehicle
DMSO stock solvent; drug-free buffer controls and fluorescence-minus-one controls for iBH3 normalization.
Co-treatment
None.
Reported limits
No catalog lot, analytical form confirmation, or sabutoclax-specific fitted potency reported in the read text; exact graph values not reconstructed.
Methods and source locations

Compound reported in the paper: Sabutoclax; Compound label in the paper: Sabutoclax

Reported research material; no equivalence to a current Adooq lot or independent stereochemical lot verification is established.

Figures 1 and 2, row labeled Sabutoclax; Methods Sec3–Sec7; Results Sec8 and Discussion Sec9

Direct mitochondrial cytochrome c release across dependency panel including BAX/BAK DKO: iBH3, 1 h; N ≥ 6; error bars SD. — Figure 2 row explicitly labeled Sabutoclax (graphic C; caption d); Figure 1; Discussion Sec9

Intact-cell killing in the antiapoptotic dependency panel: Annexin V/Hoechst after 24 h; N ≥ 3; error bars SD. — Figure 2 row labeled Sabutoclax, right plot; Results Sec8; Methods Sec6

In Vivo Studies

In Bcl-2-transgenic mice that had not developed aggressive lymphoma, a single 42 mg/kg intraperitoneal dose of compound 11 was associated with >30% spleen-weight reduction at 24 h. The experiment reported two treated mice and mild gastrointestinal toxicity. This short-term splenic response does not establish tumor regression, survival benefit or general tolerability. [1]

Short-term splenic response in Bcl-2-transgenic mice

Animal study · Bcl-2-transgenic mice with B-cell accumulation in spleen; animals had not yet developed aggressive lymphoma. [1]

A single 42 mg/kg intraperitoneal dose of compound 11 was associated with >30% spleen-weight reduction at the 24-h endpoint. Only two treated animals were reported; mild gastrointestinal toxicity was noted.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Spleen weight relative to control-treated Bcl-2-transgenic micereduction >30% (authors’ narrative; two treated mice).[1]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Single injection
Treatment course
Spleen endpoint at 24 h
Vehicle
Ethanol/Cremophor EL/saline, 10:10:80
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Compound 11, single dose
42 mg/kg
Matched transgenic mice receiving formulation without compound; other isomers were comparator groups.Authors report >30% spleen-weight reduction and mild gastrointestinal toxicity. This is a short-term splenic pharmacodynamic endpoint, not tumor regression or survival.[1]
Compound 11, single dose
Model: Age- and sex-matched B6-line Bcl-2-transgenic mice, before development of aggressive lymphoma; two treated mice reported.
Reported limits: Exact control-group count and sex/age values are not specified in the read main text; no inferential significance reported for this comparison.
Methods and source locations

Compound reported in the paper: Sabutoclax; Compound label in the paper: Compound 11 (BI-97C1)

Reported research material; no equivalence to a current Adooq lot or independent stereochemical lot verification is established.

Figure 4D; Results and Discussion Bcl-2-transgenic paragraph; Experimental Section S17–S18

Spleen weight relative to control-treated Bcl-2-transgenic mice: Spleen removed and weighed at 24 h; Figure 4D instead plots percent maximum reduction with mean ± SE. — Results and Discussion Bcl-2-transgenic paragraph; Figure 4D; Mouse Experiments

Compound 11, single dose · Figure 4D; Results and Discussion Bcl-2-transgenic paragraph; Experimental Section: Bcl-2 Transgenic Mice Studies and Mouse Experiments

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1228108-65-3
Applications Bcl-2 inhibitor
Formula C42H40N2O8
Molecular Weight 700.78
Synonyms BI-97C1
SMILES
CC1=C(C(=C2C=C(C(=C(C2=C1)C(=O)NC[C@H](C)C3=CC=CC=C3)O)O)O)C4=C(C=C5C(=C4O)C=C(C(=C5C(=O)NC[C@H](C)C6=CC=CC=C6)O)O)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 93 mg/mL (132.7 mM)
Water Insoluble
Ethanol Warmed: 50 mg/mL (71.34 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Wei J, Stebbins JL, Kitada S, et al. BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. Journal of medicinal chemistry (2010). PMID: 20443627 DOI: 10.1021/jm1001265 Source material
  2. [2] Villalobos-Ortiz M, Ryan J, Mashaka TN, et al. BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics. Cell death and differentiation (2020). PMID: 31332296 DOI: 10.1038/s41418-019-0391-9 Source material
  3. [3] Graham CD, Kaza N, Pruitt HC, et al. BH3 mimetics suppress CXCL12 expression in human malignant peripheral nerve sheath tumor cells. Oncotarget (2017). PMID: 28055968 DOI: 10.18632/oncotarget.14398 Source material

Publications

1 publication citing this product

  1. Christopher D. Graham, .et al. , Oncotarget, 2017, Jan 31; 8(5): 8670-8678 PMID: 28055968

Added to your cart

View Cart Checkout
Loading...